[Efficacy and safety of programmed death-1 inhibitor in the treatment of relapsed/refractory classical Hodgkin's lymphoma].
Shan DD, Liu HM, Liu W, Huang WY, Lyu R, Deng SH, Yi SH, An G, Xu Y, Sui WW, Wang TY, Fu MW, Zhao YZ, Qiu LG, Zou DH.
Shan DD, et al. Among authors: an g.
Zhonghua Xue Ye Xue Za Zhi. 2023 Jul 14;44(7):555-560. doi: 10.3760/cma.j.issn.0253-2727.2023.07.005.
Zhonghua Xue Ye Xue Za Zhi. 2023.
PMID: 37749034
Free PMC article.
Chinese.